MENLO PARK, Calif., Sept. 5, 2017 /PRNewswire/
-- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology
market, today announced that Anja Krammer, president and co-founder of BioPharmX, will present at
the Rodman & Renshaw 19th Annual Global Investment Conference next week.
Ms. Krammer is scheduled to present on September 12 from 3:25 – 3:50 p.m.
EDT in the Louis Room at the Lotte New York Palace Hotel. A live webcast of the presentation will be available at
http://www.wsw.com/webcast/rrshq27/bpmx and will be archived for 90 days following the presentation.
The Rodman & Renshaw 19th Annual Global Investment Conference hosts approximately 200 public and private
companies presenting to an audience of approximately 2,000 attendees. The conference focuses on tracks dedicated to
healthcare, natural resources, technology, media and telecommunications, and cleantech.
About BioPharmX® Corporation
BioPharmX Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical company, which seeks to
provide products through proprietary platform technologies for prescription, over-the-counter (OTC), and supplement applications
in the health and wellness markets, including dermatology and women's health. To learn more about BioPharmX,
visit www.BioPharmX.com.
Forward-Looking Statements
The information in this press release contains forward-looking statements and information within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which
are subject to the "safe harbor" created by those sections. This press release contains forward-looking statements about the
company's expectations, plans, intentions, and strategies, including, but not limited to, statements regarding the safety and
medical effects of BPX-01, the effect BPX-01 may have on the treatment of acne, the commencement and results of future trials of
BPX-01 and the size of such trials, continued and consistent results in future tests of BPX-01 and absence of side effects of
future use of BPX-01. These forward-looking statements may be identified by words such as "plan," "expect," "anticipate,"
"believe" or similar expressions that are intended to identify such forward-looking statements.
These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully
materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such
forward-looking statements. The risks and uncertainties include those described in the company's filings with the Securities and
Exchange Commission, including our annual report on Form 10-K for the period ended Jan. 31, 2017 and our quarterly report on
Form 10-Q for the period ended April 30, 2017. Given these risks and uncertainties, you are
cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this news
release are made only as of the date hereof, and the company undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under
applicable securities law.
BioPharmX is a registered trademark of BioPharmX, Inc.
View original content with multimedia:http://www.prnewswire.com/news-releases/biopharmx-to-present-at-rodman--renshaw-19th-annual-global-investment-conference-300511818.html
SOURCE BioPharmX Corporation